Tyra Biosciences (NASDAQ:TYRA - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Tyra Biosciences Trading Down 4.8 %
TYRA traded down $0.50 during trading hours on Tuesday, hitting $10.00. The company's stock had a trading volume of 733,966 shares, compared to its average volume of 256,267. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The company has a 50-day simple moving average of $9.73 and a 200 day simple moving average of $13.59. The firm has a market capitalization of $530.90 million, a PE ratio of -6.21 and a beta of 1.17.
Analyst Ratings Changes
Several research firms have commented on TYRA. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, UBS Group assumed coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $30.83.
Read Our Latest Analysis on Tyra Biosciences
Insider Buying and Selling at Tyra Biosciences
In other news, Director Nina S. Kjellson sold 5,401 shares of the firm's stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares of the company's stock, valued at $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 15.40% of the company's stock.
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
